Avanafil: The Second-Generation Treatment of Erectile Dysfunction-Reference-Cited by-同舟云学术

Avanafil: The Second-Generation Treatment of Erectile Dysfunction

Published:2016-08-23 Issue: Volume: Page:61-69
ISSN:2397-6764
Container-title:European Medical Journal
language:
Short-container-title:EMJ

Author:

Corona Giovanni¹,Maggi Mario²,Jannini Emmanuele A.³

Affiliation:

1. Endocrinology Unit 1, Maggiore-Bellaria Hospital, Medical Department, Azienda-Usl Bologna, Bologna, Italy

2. Sexual Medicine and Andrology Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy

3. Sexual Medicine and Andrology Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy; Endocrinology, Andrology, and Medical Sexology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy

Abstract

The main objectives of erectile dysfunction (ED) management are to control and reduce associated organic cardiovascular risk factors and to restore the capacity to obtain and maintain a rigid penile erection. Since oral phosphodiesterase (PDE)-5 inhibitors have a demonstrated efficiency in the number and duration of erections in patients with ED with a favourable benefit-to-risk ratio, they have been recommended in European guidelines as the first-line medical therapy for ED. In January 2016, we published a comprehensive review and meta-analysis on the safety and efficacy of avanafil, a novel second-generation PDE-5 inhibitor. This review aims to shed a special spotlight on the key aspects of this meta-analysis and to discuss how avanafil can provide an added value in the management of ED over first-generation agents.

Publisher

European Medical Group

Subject

General Medicine

Reference204 articles.

1. 1. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. Jama. Jul 7 1993;270(1):83-90.

3. 2. Johannes CB, Araujo AB, Feldman HA, et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. The Journal of urology. Feb 2000;163(2):460-463.

5. 3. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU international. Jul 1999;84(1):50-56.